Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Pharmacokinetics: Overview01:10

Pharmacokinetics: Overview

Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV) administration...
Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction Note: Influence of hypobaric hypoxia on leptin levels in men.

International journal of obesity (2005)·2024
Same author

Immunomodulation profile of the biosimilar trastuzumab MYL-1401O in a bioequivalence phase I study.

Scientific reports·2024
Same author

Liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) methods for the therapeutic drug monitoring of cytotoxic anticancer drugs: An update.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences·2024
Same author

Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs.

ESMO open·2023
Same author

Corrigendum to "Validation and clinical application of a multiplex high performance liquid chromatography - Tandem mass spectrometry assay for the monitoring of plasma concentrations of 12 antibiotics in patients with severe bacterial infections" [J. Chromatogr. B 1157 (2020) 122160].

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences·2022
Same author

A battery of tandem mass spectrometry assays with stable isotope-dilution for the quantification of 15 anti-tuberculosis drugs and two metabolites in patients with susceptible-, multidrug-resistant- and extensively drug-resistant tuberculosis.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences·2022
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

[Erythema multiforme : target deciphering].

Revue medicale suisse·2026
See all related articles

Related Experiment Video

Updated: Jun 4, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

[Pharmacovigilance update].

F Livio1, J Biollaz, T Buclin

  • 1Division de pharmacologie et toxicologie cliniques, Département de médecine, CHUV, 1011 Lausanne. francoise.livio@chuv.ch

Revue Medicale Suisse
|February 12, 2011
PubMed
Summary
This summary is machine-generated.

This review covers key pharmacovigilance updates, including drug suspensions for cardiovascular risks and vaccine safety. It highlights interactions, pregnancy concerns, and rare adverse events for various medications.

Related Experiment Videos

Last Updated: Jun 4, 2026

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

Area of Science:

  • Pharmacovigilance and Drug Safety
  • Clinical Pharmacology
  • Pharmaceutical Risk Management

Context:

  • Recent pharmacovigilance data reveals significant safety concerns and updates for several medications.
  • Regulatory actions have been taken, including suspensions and warnings, based on emerging risk profiles.
  • The review synthesizes critical information impacting clinical practice and patient safety.

Purpose:

  • To provide a comprehensive overview of major pharmacovigilance updates.
  • To inform healthcare professionals about drug safety issues, including cardiovascular risks, drug interactions, and rare adverse events.
  • To emphasize the importance of ongoing safety monitoring and appropriate drug utilization.

Summary:

  • Rosiglitazone and sibutramine were suspended due to cardiovascular risks.
  • H1N1 vaccine safety is comparable to seasonal influenza vaccines.
  • Concerns identified include tamoxifen efficacy reduction by paroxetine, debated antidepressant use in pregnancy, potential increased venous thromboembolism risk with drospirenone-containing contraceptives, and cardiac interval changes with saquinavir.
  • Rivastigmine transdermal patch use, lamotrigine-induced aseptic meningitis, and long-term proton pump inhibitor use and fracture risk are also discussed.

Impact:

  • Informs clinical decision-making regarding medication selection and patient monitoring.
  • Highlights the need for updated prescribing guidelines and patient counseling.
  • Contributes to the ongoing effort to ensure medication safety and optimize therapeutic outcomes.